中文摘要：

目的 观察中药“通心痹合剂”治疗冠状动脉粥样硬化性心脏病（CHD、简称冠心病）心绞痛患者的临床疗效及改善内皮细胞损伤、抑制血小板活化、抗炎症反应的影响。方法 选择60例符合条件的CHD心绞痛患者,应用随机数字表法分入治疗组和对照组各30例。治疗组在基础治疗上加用中药“通心痹合剂”口服,对照组在基础治疗上加用“心可舒”片,每次4片,每日3次,2组均连续服药4周为1个疗程,观察CHD心绞痛患者临床症状及血浆血管性假性血友病因子（v WF）、α颗粒膜蛋白140（GMP-140）、血清C反应蛋白（CRP）和肿瘤坏死因子α（TNF-α）、白细胞介素6（IL-6）治疗前后水平变化。结果 （1）治疗组总有效率93.33%,明显高于对照组83.33%,且能显著缓解冠心病心绞痛发作;（2）治疗组v WF、GMP-140、CRP、TNF-α、IL-6含量均明显低于对照组（P〈0.05,P〈0.01）;结论 中药“通心痹合剂”治疗CHD心绞痛疗效确切,可显著改善心绞痛发作;其机理可能改善其内皮细胞损伤、抑制血小板活化、抗动脉炎症反应、从而达到治疗CHD的目的。

英文摘要：

Objective ： To observe the clinical effect of Tongxinbihe Mixture on the treatment of coronary atherosclerotic heart disease（ CHD）patients with angina pectoris and the improvement of endothelial cell injury,platelet activation inhibition and anti - inflammatory response. Methods ： 60 patients were randomly divided into a treatment group and a control group, 30 cases per group. The treatment group was added oralTongxinbihe Mixture besides basic treatment while the control group was added Xinkeshu tablets,4 pc each,3 times daily besides basic treatment. The two groups were given continuous medication for factor（ vWF）, α - granule membrane factor α （ TNF - α ）, interleukin treatment. Results：The total curative 4 weeks, a course of treatment, and the clinical symptoms, plasma yon Willebrand protein 140 （GMP- 140）, serum C -reactive protein（CRP） and tumor necrosis - 6 （IL - 6） levels of the patients were observed before and after the effect rate of the treatment group was 93.33%, significantly higher than the rate （83.33%）of the -α andlL-6 of control group, and could significantly relieve angina pectoris attack. The vWF, GMP - 140, CRP, TNF f the treatment group were significantly lower than those of the control group （P 〈 0. 05, P 〈 0. 01 ） Conclusion：Tongxinbihe Mixture has effect on the treatment of angina pectoris patients and can significantly improve angina pectoris attack, and its mechanism may improve endothelial cell injury, inhibit platelet activation and resist artery inflammation so as to achieve the purpose of treatment of CHD.